Corcept Therapeutics Files Routine 8-K on Jan 2, 2024
Ticker: CORT · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1088856
| Field | Detail |
|---|---|
| Company | Corcept Therapeutics INC (CORT) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, administrative
TL;DR
**Corcept Therapeutics filed a routine 8-K, no new material news.**
AI Summary
Corcept Therapeutics Incorporated filed an 8-K on January 2, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits'. This filing is a routine update, primarily confirming the company's registration details, including its incorporation in Delaware, its business address at 149 Commonwealth Drive, Menlo Park, CA, and its common stock trading under the symbol CORT on The Nasdaq Stock Market. For investors, this filing is a standard procedural disclosure and doesn't contain new financial or operational news that would immediately impact the stock price, but it confirms the company's active compliance with SEC regulations.
Why It Matters
This filing is a standard procedural update, confirming Corcept Therapeutics' compliance with SEC reporting requirements. It doesn't contain new material information that would directly affect the stock price.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative and does not introduce any new financial, operational, or legal risks to the company.
Analyst Insight
A smart investor would recognize this as a routine administrative filing with no immediate impact on Corcept Therapeutics' stock. No specific action is warranted based solely on this 8-K.
Key Players & Entities
- Corcept Therapeutics Incorporated (company) — the registrant filing the 8-K
- Delaware (company) — state of incorporation for Corcept Therapeutics
- CORT (company) — trading symbol for Corcept Therapeutics' Common Stock
- The Nasdaq Stock Market (company) — exchange where Corcept Therapeutics' Common Stock is registered
- 149 Commonwealth Drive, Menlo Park, CA 94025 (dollar_amount) — business address of Corcept Therapeutics
FAQ
What is the purpose of this 8-K filing by Corcept Therapeutics Incorporated?
The 8-K filing by Corcept Therapeutics Incorporated on January 2, 2024, is a 'Current Report' filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'. It primarily serves as a routine disclosure of company information and compliance.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is Corcept Therapeutics Incorporated.
Where is Corcept Therapeutics Incorporated incorporated?
Corcept Therapeutics Incorporated is incorporated in Delaware.
What is the trading symbol and the exchange where Corcept Therapeutics' common stock is registered?
Corcept Therapeutics' common stock trades under the symbol CORT and is registered on The Nasdaq Stock Market.
What is the business address and phone number of Corcept Therapeutics Incorporated?
The business address of Corcept Therapeutics Incorporated is 149 Commonwealth Drive, Menlo Park, CA 94025, and its telephone number is (650) 327-3270.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-01-02 08:06:00
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CORT The Nasdaq Stock Mar
Filing Documents
- d676865d8k.htm (8-K) — 24KB
- d676865dex991.htm (EX-99.1) — 6KB
- g676865g0102065800099.jpg (GRAPHIC) — 5KB
- 0001193125-24-000247.txt ( ) — 155KB
- cort-20240102.xsd (EX-101.SCH) — 3KB
- cort-20240102_lab.xml (EX-101.LAB) — 17KB
- cort-20240102_pre.xml (EX-101.PRE) — 11KB
- d676865d8k_htm.xml (XML) — 3KB
01
Item 8.01. Other Events On January 2, 2024, Corcept Therapeutics Incorporated ("Corcept") issued a press release announcing that the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals does not infringe any asserted claims of Corcept's U.S. Patents 10,195,214 and 10,842,800, both of which concern methods of safely administering Korlym with drugs that are strong CYP3A4 inhibitors. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibits No. Description 99.1 Press Release dated January 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORCEPT THERAPEUTICS INCORPORATED Date: January 2, 2024 By: /s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer